Search

Your search keyword '"Verbeke, Sofie"' showing total 172 results

Search Constraints

Start Over You searched for: Author "Verbeke, Sofie" Remove constraint Author: "Verbeke, Sofie"
172 results on '"Verbeke, Sofie"'

Search Results

2. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas

3. International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer—Principles of Classification and Emerging Clinical Utility

5. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer

7. International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer—Principles of Classification and Emerging Clinical Utility

8. Shallow whole-genome sequencing: a useful, easy to apply molecular technique for CNA detection on FFPE tumor tissue—a glioma-driven study

10. Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping

14. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial

15. Suppl Data 2 from Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer

16. Data from Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer

17. Suppl. Data 1 from Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer

18. Supplementary Figures, Tables, Notes from Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer

19. Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer

20. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer

21. Abstract LB171: WSI based prediction of TP53 mutations identifies aggressive disease phenotype in prostate cancer

22. Radiotherapy Use in Muscle-Invasive Bladder Cancer: Review of the Guidelines and Impact of Increased Awareness in Patient Referral at a Tertiary Center in Belgium

24. Genomic determinants of patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer.

27. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials

30. Abstract 41: Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer

31. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic castration-sensitive prostate cancer: A pooled analysis of the STOMP and ORIOLE trials.

35. MP24-10 NEWLY-DIAGNOSED LOW-VOLUME METASTATIC PROSTATE CANCER; IS THERE A PLACE FOR CYTOREDUCTIVE RADICAL PROSTATECTOMY?

36. Vulvar pagetoid urothelial intraepithelial neoplasia: a case report

37. Additional file 3 of Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial

39. Additional file 1 of Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial

40. Genomic features of lung-recurrent hormone sensitive prostate cancer

43. Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential

44. Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma

47. Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results.

48. Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples

49. Dichotomous histopathological assessment of ductal carcinomain situof the breast results in substantial interobserver concordance

Catalog

Books, media, physical & digital resources